PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Heart vests to identify those at high risk of sudden cardiac death

In the UK, heart rhythms affect around two million people and can cause sudden death.

A re-useable heart vest developed by researchers from University College London (UCL) could potentially be used to predict and identify people who are at risk of sudden cardiac death.

The study found that the electrocardiographic imaging (ECGI) vest could benefit standard care today because of its re-usability and time efficiency.

Electric signals cause the heart to contract, which regulates its heartbeat. When electrical signals, which cause the heart to contract and regulate the heartbeat, are disrupted, heart rhythm disorders can occur.

Heart rhythms affect around two million people in the UK and can cause sudden death.

Previously, detailed mapping of the heart’s electric activity required inserting a catheter inside the heart cavity or using single-use devices, which were costly, time-consuming to set up and involved radiation.

Funded by the British Heart Foundation, the vest combines electrical data from 256 sensors and detailed MRI images of heart structures to generate 3D digital models of the heart and the electrical waves of activity flowing through it.

After assessing 77 patients, the study concluded that the ECGI vest was reliable and durable to use.

Additionally, the vest could also be “used to assess the impact of drugs, new cardiac devices and lifestyle interventions on heart health,” said Dr Gaby Captur, UCL Institute of Cardiovascular Science and the Royal Free Hospital, London.

The device would help clinicians identify those in need of an implantable cardioverter defibrillator to monitor heart rhythm and shock the heart back into a normal rhythm when necessary.

The ECGI vest has successfully been used in 800 patients and is currently being used to map the hearts of people with diseases including hypertrophic cardiomyopathy and dilated cardiomyopathy.

“We believe the vest we have developed could be a quick and cost-effective screening tool and that the rich electrical information it provides could help us better identify people’s risk of life-threatening heart rhythms in the future,” added Captur.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026